Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Kuangli Bio-Tech Holdings Co's Debt-to-EBITDA or its related term are showing as below:
TPE:6431'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -36.98 Med: -4.08 Max: 3.24
Current: -5.89
During the past 13 years, the highest Debt-to-EBITDA Ratio of Kuangli Bio-Tech Holdings Co was 3.24. The lowest was -36.98. And the median was -4.08.
TPE:6431's Debt-to-EBITDA is ranked worse than 100% of 1554
companies
in the Consumer Packaged Goods industry
Industry Median: 2.105
vs TPE:6431: -5.89
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Kuangli Bio-Tech Holdings Co Debt-to-EBITDA Related Terms
Kuangli Bio-Tech Holdings Co Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:6431 vs PG, CL, KVUE: Debt-to-EBITDA Comparison
For the Household & Personal Products subindustry, Kuangli Bio-Tech Holdings Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kuangli Bio-Tech Holdings Co Debt-to-EBITDA vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Kuangli Bio-Tech Holdings Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Kuangli Bio-Tech Holdings Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Kuangli Bio-Tech Holdings Co (TPE:6431) has a Debt-to-EBITDA of -9.63 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Kuangli Bio-Tech Holdings Co. According to the industry distribution chart, Kuangli Bio-Tech Holdings Co ranks #999999 out of 1554 companies in the Consumer Packaged Goods industry.
Is Kuangli Bio-Tech Holdings Co's Debt-to-EBITDA too high?
Kuangli Bio-Tech Holdings Co's current Debt-to-EBITDA is -9.63. Based on the distribution chart, Kuangli Bio-Tech Holdings Co ranks #999999 out of 1554 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers. Overall, Kuangli Bio-Tech Holdings Co has a GF Score™ of 65/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kuangli Bio-Tech Holdings Co's Debt-to-EBITDA compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, Kuangli Bio-Tech Holdings Co ranks #999999 out of 1554 companies for Debt-to-EBITDA. This places Kuangli Bio-Tech Holdings Co in the lower half of its industry. The industry median Debt-to-EBITDA is 2.11. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Consumer Packaged Goods company?
The median Debt-to-EBITDA among Consumer Packaged Goods companies is 2.11, based on 1,554 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Kuangli Bio-Tech Holdings Co. For the Consumer Packaged Goods industry, the median Debt-to-EBITDA is 2.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kuangli Bio-Tech Holdings Co's current Debt-to-EBITDA is -9.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kuangli Bio-Tech Holdings Co stock overvalued right now?
Based on GuruFocus' analysis, Kuangli Bio-Tech Holdings Co (TPE:6431) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$10.67, compared to a current price of NT$19.10 — trading 79% above its estimated fair value. The current Debt-to-EBITDA is -9.63. Kuangli Bio-Tech Holdings Co's overall GF Score™ is 65/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Kuangli Bio-Tech Holdings Co (TPE:6431), the current Debt-to-EBITDA is -9.63 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kuangli Bio-Tech Holdings Co (TPE:6431) Overvalued in 2026?
Based on GuruFocus' analysis, Kuangli Bio-Tech Holdings Co stock appears to be overvalued.
The current stock price of NT$19.10 is trading 79% above its estimated GF Value™ of NT$10.67.
GuruFocus considers Kuangli Bio-Tech Holdings Co to be Significantly Overvalued.
Key valuation signals for TPE:6431:
Debt-to-EBITDA: -9.63
GF Value™: NT$10.67 vs. price of NT$19.10 (79% above fair value)
No single metric tells the full story. See the TPE:6431 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kuangli Bio-Tech Holdings Co Ltd is mainly engaged in the manufacture and trading of various types of panels (LENS), such as mobile phone panels, digital camera windows, PDA panels, and instrument panels. The company is also engaged in the development, manufacturing and trading of cosmetics and skin care products and other related biotechnology products. It derives revenue from Health and Wellness products, and Cosmetics and skin care products, including Lotion, Facial masks, and Other pastes. The primary source of revenue for the company is sales of cosmetic products.
65GF Score
Get the complete analysis for TPE:6431
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6431 has been successfully added to your 
